AngioDynamics, Arqit Quantum, and Apimeds Shares Plunge Over 18%

Key Facts

1AngioDynamics shares fell 20.9% to $11.23 despite reporting fiscal Q1 revenue of approximately $80.9 million.

2Arqit Quantum shares lost 18.3% after projecting preliminary second-half fiscal 2026 revenue between $355,000 and $380,000.

3Apimeds Pharmaceuticals US shares dropped 21.8% to $5.51 with no clearly identified catalyst for the loss.

AngioDynamics shares fell 20.9% to $11.23 despite the company reporting fiscal Q1 revenue of approximately $80.9 million. Financial Modeling Prep reported that Arqit Quantum shares lost 18.3% after projecting preliminary second-half fiscal 2026 revenue between $355,000 and $380,000. Additionally, Apimeds Pharmaceuticals US shares dropped 21.8% to $5.51 with no clearly identified catalyst for the loss.

These sharp price movements follow the previous session where ANGO closed at $14.19 on October 7, 2026, while ARQQ closed at $22.55 and APUS closed at $7.05 on the same date. According to Financial Modeling Prep, the declines were driven by a mix of post-earnings volatility for AngioDynamics and weak forward revenue guidance for Arqit Quantum, reflecting significant pressure on small-cap equities.